Detailed FundamentalsSingle-page fundamentals layout — broad valuation, growth, profitability, health, competitors, top funds & analyst detail.
Price chartUnavailable
Loading price history...
52-Week Range
Trailing twelve months
$54.11$92.59
Daily Price Range
Day up 0.1%%
$85.27$87.34
Volume
vs 4M avg
3M4M avg
Profile
Identity and capital structure
SectorEquity
IndustryCommon Stock
Market Cap$32.7B
Short % of Float—
Employees—
Sales—
Shares Outstanding377,365,021
IPO Date—
Last Reported Qtr.—
Next Qtr. Report—
Headquarters—
Homepagewww.dxcm.com
DexCom Inc — DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dex….· via yahoo
Warnings
1 signal
Live
- No material red flags detected in fundamental screen
Scores
0–100 · higher is better except where noted
Value
—
Growth
—
Quality
—
Sentiment
—
Insider Sent.
—
Piotroski F
—
Altman Z
—
Consensus rating unavailable — no analyst coverage on file for DXCM.
Price targets unavailable — no 12-month targets on file for DXCM.
Valuation Engine
DCF Intrinsic Valuation Model
Run an interactive 5-year Discounted Cash Flow valuation on DXCM, calculate Margin of Safety, and stress-test WACC discount hurdles.
Data as ofQuote: Live · Insiders: Live · Fundamentals/Benchmarks: Curated · Vantage Composite · 1 warnings surfacedSep 29, 2026, 1:54 AM UTC